Physician profile
Anthony Guida
NPI 1467443291
$6,648.23
in general payments reported to CMS, 2019-2025
34 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $543 · 2021: $665 · 2022: $901 · 2023: $930 · 2024: $1,193 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,531.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $776.47 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Pfizer INC. | $604.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $581.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $497.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $482.96 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $417.08 | 2019-2025 | |
| Lilly USA, LLC | $381.60 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $377.80 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $315.99 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $312.77 | 2019-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $240.11 | 2019-2025 | Livalo, Zoryve |
| Amgen INC. | $229.72 | 2022-2025 | Repatha, Otezla, Otezla |
| Daiichi Sankyo INC. | $219.91 | 2019-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $212.77 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $191.35 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $152.99 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $131.76 | 2019-2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $83.18 | 2025 | Recorlev |
| Takeda Pharmaceuticals U.S.A., INC. | $56.28 | 2024 | Glassia |
| Astellas Pharma US INC | $53.71 | 2023 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $41.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.53 | 2025 | |
| Esperion Therapeutics, INC. | $29.15 | 2025 | Nexletol |
| Axsome Therapeutics, INC. | $28.42 | 2025 | Auvelity |
| Lundbeck LLC | $21.94 | 2024 | Rexulti |
| Dexcom, INC. | $21.81 | 2023 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $21.57 | 2025 | Flexitouch Plus, Nimbl |
| Avvisto Therapeutics, LLC | $21.31 | 2024 | Cycloset |
| Corcept Therapeutics | $20.84 | 2024 | Korlym |
| Scilex Pharmaceuticals INC. | $20.50 | 2021 | |
| Intuity Medical INC | $19.41 | 2022 | |
| Dynavax Technologies Corporation | $15.50 | 2024 | Heplisav-B |
| Vistapharm, INC. | $14.05 | 2021 | |
| Philips North America LLC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Guida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.